Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Micah Denay McCumber, BS, MS, Aaron Mark Wendelboe, PhD MS, Janis Campbell, PhD GISP, Kai Ding, PhD, Michele G Beckman, MPH, Nimia L Reyes, MD MPH, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3463.

https://doi.org/10.1182/blood-2019-130604

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Alex C. Spyropoulos, MD, Walter Ageno, Gregory W. Albers, MD, C. Gregory Elliott, MD, Jonathan L. Halperin, MD, William R. Hiatt, Gregory Maynard, MD, P. Gabriel Steg, MD, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Gary E. Raskob, PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 3669.

https://doi.org/10.1182/blood-2019-122621

Published: 2019

Journal Articles

Risk Factors Associated with 6-Month Recurrent VTE Among Patients in Two Large Population-Based Surveillance Systems

Alys Adamski, PhD MPH, Aaron Mark Wendelboe, PhD MS, Thomas L. Ortel, MD PhD, Gary E. Raskob, PhD, Nimia Reyes, MD MPH, Ibrahim Saber, MD, Karon Abe, PhD, Michele Beckman, PhD MPH

Blood (2019) 134 (Supplement_1): 3444.

https://doi.org/10.1182/blood-2019-126903

Published: 2019

Journal Articles

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Alex C. Spyropoulos, MD, Concetta Lipardi, MD PhD, Alexander T Cohen, MBBS, MSc, MD, Biljana Vučković, MD PhD, Jianfeng Xu, PhD, Wentao Lu, PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD, Gary E. Raskob, PhD

Blood (2019) 134 (Supplement_1): 3671.

https://doi.org/10.1182/blood-2019-122945

Published: 2019

Journal Articles

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Alex C. Spyropoulos, MD, Gary E. Raskob, PhD, Alexander T Cohen, MBBS, MSc, MD, Walter Ageno, Jeffrey I. Weitz, MD, Theodore E. Spiro, MD, Wentao Lu, PhD, Concetta Lipardi, MD PhD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 2441.

https://doi.org/10.1182/blood-2019-122930

Published: 2019

Journal Articles

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MBBS, MSc, MD, Jeffrey I. Weitz, MD, Walter Ageno, Yoriko De Sanctis, MS, Wentao Lu, PhD, Jianfeng Xu, PhD, John Albanese, BS, MBA, Chiara Sugarmann, BSN, MSHS, Concetta Lipardi, MD PhD, Theodore E. Spiro, MD, Elliot S. Barnathan, MD

Blood (2019) 134 (Supplement_1): 163.

https://doi.org/10.1182/blood-2019-122934

Published: 2019

Journal Articles

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

Jeffrey I. Weitz, MD, Gary E. Raskob, PhD, Alex C. Spyropoulos, MD, Alexander T Cohen, MD, Theodore E. Spiro, MD, Yoriko De Sanctis, MS, Jianfeng Xu, PhD, Eunyoung Suh, PhD, Wentao Lu, PhD, Concetta Lipardi, MDPhD, Elliot S. Barnathan, MD

Blood (2018) 132 (Supplement 1): 1236.

https://doi.org/10.1182/blood-2018-99-111911

Published: 2018

Journal Articles

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Gary E. Raskob, PhD, Nick Van Es, MD, Peter Verhamme, MD PhD, Marc Carrier, MD, Marcello Di Nisio, MD, David A. Garcia, MD, Michael A. Grosso, MD, Ajay K. Kakkar, MBBS, Michael J. Kovacs, MD, Michele F. Mercuri, MD PhD FAHA, Guy Meyer, MD, Annelise Segers, MD, Minggao Shi, PhD, Tzu-Fei Wang, MD, Erik Yeo, MD FACP, FRCPC, George Zhang, PhD, Jeffrey I. Zwicker, MD, Jeffrey I. Weitz, MD, Harry R. Büller, MD PhD

Blood (2017) 130 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-6.LBA-6

Published: 2017

Journal Articles

Hospital Associated Venous Thromboembolism in Oklahoma County

Natalie Feland, RN, Aaron Mark Wendelboe, PhD MS, Micah Denay McCumber, BS, MS, Kai Ding, PhD, Dale Bratzler, DO, Nimia Reyes, MD, MPH, Michele Beckman, MPH, Gary E Raskob, PhD

Blood (2016) 128 (22): 416.

https://doi.org/10.1182/blood.V128.22.416.416

Published: 2016

Journal Articles

Incidence of Venous Thromboembolism Estimated Using Hospital Discharge Data: Differences Between Event-Based Estimates and Patient-Based Estimates

Aaron M Wendelboe, PhD, Janis Campbell, PhD, Micah McCumber, MS, Kai Ding, PhD, Dale Bratzler, DO, Michele Beckman, MPH, Nimia Reyes, MD MPH, Gary E. Raskob, PhD

Blood (2014) 124 (21): 3508.

https://doi.org/10.1182/blood.V124.21.3508.3508

Published: 2014

Journal Articles

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Harry Roger Buller, MD PhD, Claudette Bethune, PhD, Sanjay Bhanot, MDPhD, David Gailani, MD, Brett P. Monia, PhD, Gary E. Raskob, PhD, Annelise Segers, Peter Verhamme, MD PhD, Jeffrey I. Weitz, MDFRCPC

Blood (2014) 124 (21): LBA-1.

https://doi.org/10.1182/blood.V124.21.LBA-1.LBA-1

Published: 2014

Journal Articles

Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data

Alexander Cohen, MD, Alexander S. Gallus, MD, Giancarlo Agnelli, MD, Harry R Buller, MD PhD, Raphael Pak, PhD, Anthony R. Porcari, PhD PharmD, Gary E. Raskob, PhD, Jeffrey I. Weitz, MDFRCPC, Takaharu Yamabe, PhD

Blood (2014) 124 (21): 1543.

https://doi.org/10.1182/blood.V124.21.1543.1543

Published: 2014

Journal Articles

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Gary E Raskob, PhD, Harry Buller, MD, PhD, Pantep Angchaisuksiri, MD, Doyeun Oh, MD, PhD, Zoltan Boda, MD, PhD, DSc, Roger M. Lyons, MD, Jeffrey I. Weitz, MD, George Zhang, PhD, Hans J Lanz, MD, Michele Mercuri, MD, PhD, FAHA

Blood (2013) 122 (21): 211.

https://doi.org/10.1182/blood.V122.21.211.211

Published: 2013

Journal Articles

Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism

Giancarlo Agnelli, MD, Harry Roger Buller, MD, PhD, Alexander Cohen, MD, Madelyn Curto, DVM, Alexander S. Gallus, M.D., Margot R. Johnson, MD, BSC, Anthony R. Porcari, PhD, PharmD, Gary E Raskob, PhD, Jeffrey I. Weitz, MD

Blood (2012) 120 (21): LBA-1.

https://doi.org/10.1182/blood.V120.21.LBA-1.LBA-1

Published: 2012

Journal Articles

Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.

Jeffrey I. Weitz, MD, FACP, FRCP, Charlie Cao, Ph.D., Bengt Eriksson, MD, William D. Fisher, MD, Stuart Kupfer, MD, Gary E Raskob, PhD, Jeffrey Spaeder, MD, Alexander GG Turpie, MD

Blood (2009) 114 (22): 170.

https://doi.org/10.1182/blood.V114.22.170.170

Published: 2009

Journal Articles

Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

Michael Rud Lassen, MD, Alexander S Gallus, MD, Graham F Pineo, MD, Gary E Raskob, PhD, the ADVANCE-1 Investigators

Blood (2008) 112 (11): 31.

https://doi.org/10.1182/blood.V112.11.31.31

Published: 2008

NARROW

Incidence of VTE Among Patients with a Cancer Diagnosis in Oklahoma County

Association of Bleeding Severity with Mortality with Extended Thromboprophylaxis in the Medically Ill in the Mariner Trial

Risk Factors Associated with 6-Month Recurrent VTE Among Patients in Two Large Population-Based Surveillance Systems

Rivaroxaban and Extended Thromboprophylaxis in Acutely Ill Medical Patients with History of Cancer: Insights from the Magellan and Mariner Studies

Association of Bleeding Severity with Mortality with in-Hospital and Extended Thromboprophylaxis in the Medically Ill in the Magellan Trial

Increased Risk of Death in Acutely Ill Medical Patients with Asymptomatic Proximal Deep Vein Thrombosis or Symptomatic Venous Thromboembolism: Insights from the Magellan Study

Medically Ill Patients with Moderate Renal Insufficiency Have More Thrombotic and Bleeding Events Than Those with Normal Renal Function: Insights from the Magellan and Mariner Trials of Extended Thrombprophylaxis

A Randomized, Open-Label, Blinded Outcome Assessment Trial Evaluating the Efficacy and Safety of LMWH/Edoxaban Versus Dalteparin for Venous Thromboembolism Associated with Cancer: Hokusai VTE-Cancer Study

Hospital Associated Venous Thromboembolism in Oklahoma County

Incidence of Venous Thromboembolism Estimated Using Hospital Discharge Data: Differences Between Event-Based Estimates and Patient-Based Estimates

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data

Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients

Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism

Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty.

Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only